scholarly journals In Situ Forming Injectable Thermoresponsive Hydrogels for Controlled Delivery of Biomacromolecules

ACS Omega ◽  
2020 ◽  
Vol 5 (28) ◽  
pp. 17531-17542
Author(s):  
Kingshuk Dutta ◽  
Ritam Das ◽  
Jing Ling ◽  
Rafael Mayoral Monibas ◽  
Ester Carballo-Jane ◽  
...  
Keyword(s):  
Controlled Delivery ◽  
In Situ Forming ◽  
Thermoresponsive Hydrogels

scholarly journals Pharmacokinetic Studies of an In Situ Forming Gel System for Controlled Delivery of Enrofloxacin In Pigs

2018 ◽  
Vol 5 (1) ◽  
pp. 1-5
Author(s):  
Zugong Yu ◽  
Huimin Li ◽  
Fanxi Zhang Zhang ◽  
Zhenrui Zhang ◽  
Jing Tian ◽  
...  
Keyword(s):  
Controlled Delivery ◽  
Pharmacokinetic Studies ◽  
In Situ Forming ◽  
In Situ Forming Gel ◽  
Gel System

In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor

2012 ◽  
Vol 426 (1-2) ◽  
pp. 132-143 ◽  
Author(s):  
Deepak N. Kapoor ◽  
Om Prakash Katare ◽  
Sanju Dhawan
Keyword(s):  
Controlled Delivery ◽  
Fusion Inhibitor ◽  
In Situ Forming ◽  
Anti Hiv

Injectable in-situ Forming Depot Of Doxycycline Hyclate/α-Cyclodextrin Complex using PLGA for Periodontitis Treatment: Preparation, Charac-terization, and In-Vitro Evaluation

2020 ◽  
Vol 17 ◽  
Author(s):  
Elham Khodaverdi ◽  
Farhad Eisvand ◽  
Mohammad Sina Nezami ◽  
Seyedeh Nesa Rezaeian Shiadeh ◽  
Hossein Kamali ◽  
...  
Keyword(s):  
Complex Form ◽  
Docking Studies ◽  
Morphological Properties ◽  
Burst Release ◽  
Cyclodextrin Complex ◽  
Doxycycline Hyclate ◽  
Scanning Calorimetry ◽  
In Situ Forming

Background:: Doxycycline (DOX) is used in treating a bacterial infection, especially for periodontitis treatment. Objective: To reduce irritation of DOX for subgingival administration and increase the chemical stability and against enzy-matic, the complex of α-cyclodextrin with DOX was prepared and loaded into injectable in situ forming implant based on PLGA. Methods:: FTIR, molecular docking studies, X-ray diffraction, and differential scanning calorimetry was performed to char-acterize the DOX/α-cyclodextrin complex. Finally, the in-vitro drug release and modeling, morphological properties, and cellular cytotoxic effects were also evaluated. Results:: The stability of DOX was improved with complex than pure DOX. The main advantage of the complex is the al-most complete release (96.31 ± 2.56 %) of the drug within 14 days of the implant, whereas in the formulation containing the pure DOX and the physical mixture the DOX with α-cyclodextrin release is reached to 70.18 ± 3.61 % and 77.03 ± 3.56 %, respectively. This trend is due to elevate of DOX stability in the DOX/ α-cyclodextrin complex form within PLGA implant that confirmed by the results of stability. Conclusion:: Our results were indicative that the formulation containing DOX/α-cyclodextrin complex was biocompatible and sustained-release with minimum initial burst release.

Sign in / Sign up

Export Citation Format

Share Document